Galectin‐8 inhibition and functions in immune response and tumor biology
Medicinal Research Reviews · 2024-09 · 44 (5) · 2236-2265
DOI: 10.1002/med.22041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 13.04.2024. Verfasst von Edvin Purić und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Galectins, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Javna Agencija za Raziskovalno Dejavnost RS, Horizon2020.
Abstract (Originalsprache)
Galectins are among organisms' most abundantly expressed lectins (carbohydrate‐binding proteins) that specifically bind β‐galactosides. They act not only outside the cell, where they bind to extracellular matrix glycans, but also inside the cell, where they have a significant impact on signaling pathways. Galectin‐8 is a galectin family protein encoded by the LGALS8 gene. Its role is evident in both T‐ and B‐cell immunity and in the innate immune response, where it acts directly on dendritic cells and induces some pro‐inflammatory cytokines. Galectin‐8 also plays an important role in the defense against bacterial and viral infections. It is known to promote antibacterial autophagy by recognizing and binding glycans present on the vacuolar membrane, thus acting as a danger receptor. The most important role of galectin‐8 is the regulation of cancer growth, metastasis, tumor progression, and tumor cell survival. Importantly, the expression of galectins is typically higher in tumor tissues than in noncancerous tissues. In this review article, we focus on galectin‐8 and its function in immune response, microbial infections, and cancer. Given all of these functions of galectin‐8, we emphasize the importance of developing new and selective galectin‐8 inhibitors and report the current status of their development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia.
- Department of Chemistry, Lund University, Lund, Sweden.
ORCID-Profile: Edvin Purić, Ulf J Nilsson, Marko Anderluh
Förderung
- Javna Agencija za Raziskovalno Dejavnost RS
- Horizon2020
Zitieren
APA
Purić, E., Nilsson, U. J., & Anderluh, M. (2024). Galectin‐8 inhibition and functions in immune response and tumor biology. Medicinal Research Reviews, 44(5), 2236-2265. https://doi.org/10.1002/med.22041
Vancouver
Purić E, Nilsson UJ, Anderluh M. Galectin‐8 inhibition and functions in immune response and tumor biology. Medicinal Research Reviews. 2024;44(5):2236-2265. doi:10.1002/med.22041
BibTeX
@article{Puri2024,
author = {Purić, Edvin and Nilsson, Ulf J and Anderluh, Marko},
title = {Galectin‐8 inhibition and functions in immune response and tumor biology},
journal = {Medicinal Research Reviews},
year = {2024},
volume = {44},
number = {5},
pages = {2236--2265},
doi = {10.1002/med.22041}
}
EUVIMED